PrintSubscribe to The Burrill Report | Don't forget to join us on Facebook
Note to our readers:
This week we feature selected content from our sister site Burrill Mindshare. We'd like to take this opportunity to wish our readers a happy, healthy, and prosperous 2011.
Policy Victories of 2010 and the Battles Ahead in the New Year | Podcast: January 3, 2011
The Burrill Report took a break this week, but we didn't want to forget loyal podcast listeners. So, this week we borrowed the audio stream from an interview The Burrill Report's Daniel Levine did in the Fall 2010 with Jim Greenwood, CEO of the Biotechnology Industry Organization for our sister site Burrill Mindshare. The past year has been a big one on the policy front for BIO. We spoke to Greenwood about the challenges and successes of 2010 and what issues stand at the forefront of the industry's agenda in 2011. Read More Here
By The Numbers
Life Sciences Companies Raise Record Amounts of Capital
Venture financings more than double while public companies go for debt.
Life sciences companies raised record amounts of capital during 2010, a year that saw change in many parts of the world as global economies continued to recover, or be bailed out, from the devastating financial crisis of recent years. Venture financings more than doubled to $9 billion in 2010 from just over $4 billion in 2009, with most of the money raised during the first half of the year. Read More Here
Biotech Industry Market Cap: $372.44 billion (down 1.24 percent for the week ending 12/31/10)
Performance of Select Blue Chip Biotechs |
|||
| COMPANY | MARKET CAP ($B) |
CHANGE IN SHARE PRICE (%) |
|
| Amgen | $51.87 | -3.19% | |
| Gilead | $29.42 | -0.07% | |
| Celgene | $27.83 | -0.93% | |
| Biogen | $15.98 | -0.25% | |
| Genzyme | $18.44 | -0.05% | |
Biotech closes year on a down note
Closing the year, the Burrill Biotech Select Index dipped 1 percent for the week and finished the year up 16.86 percent. The biotech industry's performance benefited from a return of investor confidence in the second half of the year, particularly the final quarter as the Select index climbed 10.7 percent. Stocks ended a quiet week with the Dow Jones Industrial Average closing unchanged. Despite investors' concerns about the domestic economy and the possibility of European countries defaulting on debt, the Dow closed up 11 percent for the year. The Nasdaq Composite Index, meanwhile, rose about 17 percent for the year.
| INDEX | 12/31/09 | 12/23/10 | 12/31/10 | % CHANGE (WEEK) | % CHANGE (YEAR) |
| Burrill Select | 312.47 | 368.75 | 365.12 | -0.98% | 16.85% |
| Burrill Large Cap | 461.85 | 533.74 | 526.55 | -1.35% | 14.01% |
| Burrill Mid-Cap | 166.01 | 223.49 | 218.10 | -2.41% | 31.38% |
| Burrill Small Cap | 88.12 | 95.28 | 94.97 | -0.33% | 7.77% |
| Burrill Genomics | 159.87 | 168.19 | 163.44 | -2.82% | 2.23% |
| Burrill BioGreenTech | 126.80 | 150.95 | 152.78 | 1.21% | 20.49% |
| Burrill Diagnostics | 147.96 | 159.58 | 158.05 | -0.96% | 6.82% |
| Burrill Personalized Medicine | 91.71 | 107.31 | 106.26 | -0.98% | 15.87% |
| Canadian Biotech | 40.35 | 56.39 | 55.68 | -1.26% | 37.99% |
| NASDAQ | 2269.15 | 2665.60 | 2652.87 | -0.48% | 16.91% |
| DJIA | 10428.05 | 11573.49 | 11577.51 | 0.03% | 11.02% |
| Amex Biotech | 941.92 | 1312.86 | 1297.61 | -1.16% | 37.76% |
| Amex Pharmaceutical | 309.21 | 306.93 | 305.88 | -0.34% | -1.08% |
Gazing into his Crystal Ball
G. Steven Burrill offers his predictions for 2011.
In keeping with our annual tradition here at The Burrill Report we present Steve Burrill's predictions for the life sciences in 2011. Read More Here
A Conversation About the Future of Molecular Diagnostics
InSight with Steve Burrill: November 5, 2010
Steve Burrill sits down for an informal and frank discussion with Eli Lilly CEO John Lechleiter about how the company will navigate its way through one of the steepest patent cliffs in the industry. Read More Here
A View of the State of the Industry
Insight with Steve Burrill: October 25, 2010
Steve Burrill offers a view of the state of the industry in his opening remarks at this year's annual Burrill Personalized Medicine Meeting in San Francisco. Read More Here
Stem Cell Research Under Attack
InSight with Steve Burrill: August 30, 2010
Steve Burrill discusses a court decision that halted federal funding of human embryonic stem cell research in the United States with UCSF's Susan Fisher, CIRM's Art Torres, and iPierian CEO Michael Venuti. Read More Here
Two Wrongs
Critics of the nation's move toward government-run healthcare are misreading the FDA's Avastin decision.
Hyperbole and misdirection aren't going to solve the problem of the slippery slope towards government-run health care–it's going to hasten it. Read More Here
The Burrill Weekly Brief | May 28, 2013
The Burrill Weekly Brief | May 13, 2013
The Burrill Weekly Brief | May 06, 2013
The Burrill Weekly Brief | April 29, 2013
The Burrill Weekly Brief | April 15, 2013
The Burrill Weekly Brief | April 08, 2013
The Burrill Weekly Brief | April 01, 2013
The Burrill Weekly Brief | March 29, 2013
The Burrill Weekly Brief | March 18, 2013
The Life Sciences Delivered to Your Desktop Every Monday Morning
Click Here for a FREE subscription to The Burrill Weekly Brief
.gif)
